Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Nov 16, 2026
TickeronGET DAILY SIGNALS
Why Is Oramed Pharmaceuticals (ORMP) Stock Up +5.66% Today?

Why Is Oramed Pharmaceuticals (ORMP) Stock Up +5.66% Today?

Key Takeaways

  • Oramed Pharmaceuticals (ORMP) climbed 5.66%, or $0.21, to $3.92 in Monday afternoon trading, clawing back part of Friday's 7.94% plunge.
  • No company press release, SEC filing, analyst action, or corporate announcement accompanied the advance.
  • The primary driver appears to be dip-buying and post-earnings reversion after last week's sharp selloff.
  • Friday's slide followed third-quarter results showing diluted EPS of $0.43 but an adjusted loss of $0.16 per share, with net income falling to $18.4 million from $48.4 million a year earlier.
  • The broader small-cap healthcare tape offered little direction, and the move was concentrated in the first hour of trading.
  • Turnover was elevated, exceeding 175,000 shares by mid-afternoon against a 60-day average near 100,000.
  • News Significance Score: 19/100 – No verified news today, yet the bounce ran roughly three times the stock's typical daily swing.
  • For deeper fundamentals, explore the Price Targets, Earnings, and Forecast pages dedicated to this ticker.
  • Readers can also browse Trending AI Robots to see which automated strategies are performing best right now.

Today's Move at a Glance

Oramed Pharmaceuticals Inc. (ORMP) is a Nasdaq-listed, New York-headquartered holding company that has moved away from in-house oral insulin development and now deploys capital across a portfolio of biomedical and medtech assets. Its largest position is a stake in Alpha Tau Medical (DRTS), alongside an interest in Lifeward (LFWD) and a long-running secured loan to Scilex Holding (SCLX). Because revenue is effectively zero, its earnings swing with portfolio revaluations rather than product sales.

Shares were quoted at $3.92 on Monday afternoon, up $0.21, or 5.66%, from Friday's close of $3.71 — a confirmed move to the upside. No verified news or fundamental development explained the advance. Pre-market activity was flat and light, then the stock opened at $3.70 and surged to an intraday high of $4.05 within the first hour, a swing of nearly 10% off the low.

No Verified News or Fundamental Catalyst Found

No verified news or fundamental catalyst found to account for Monday's gain. There was no press release, no 8-K or Form 4 disclosure indicating open-market insider buying, no analyst rating change, and no corporate transaction announced before or during the session. Given the absence of a headline, the price action is most consistent with technical dip-buying after a capitulation-style session, amplified by a thin order book.

The data supports that reading. Friday's decline of 7.94% was the steepest single-session drop in 60 trading sessions and pushed the stock to a low of $3.67, its weakest level since early November. Monday's open at $3.70 was essentially a retest of that floor, and the rebound came from an oversold position with a 14-day relative strength index near 34. A single large buyer can move this stock several percent: the shares trade in a market capitalization of roughly $170 million with a float of about 32 million shares.

Post-Earnings Overhang Is Still the Dominant Variable

Friday's selloff, not Monday's bounce, is the more informative event. Oramed's third-quarter report on November 12 showed net income of $18.4 million, or $0.43 per diluted share, matching consensus. Strip out non-recurring investment gains — chiefly the revaluation of the Alpha Tau holding and income from related service agreements — and the company recorded an adjusted loss of $0.16 per share. Net income fell roughly 62% year over year, and revenue was zero after the transfer of the oral drug-delivery platform to Lifeward in March.

Management held its earnings call after the close on November 13, which means Monday was the first full session in which investors could react to the discussion as well as the numbers. The rebound suggests some holders viewed the drawdown as disproportionate to a quarter whose headline profit was inflated by accounting gains rather than eroded by operational deterioration.

Market Context and Trading Activity

Volume ran well above normal, with more than 175,000 shares changing hands by mid-afternoon versus a 60-day average of roughly 100,000 — an elevated reading that lends some credibility to the bounce, even without news. The move was not mirrored by any obvious sector-wide catalyst; small-cap healthcare and biotech indices gave no clear directional lead, reinforcing that this was an idiosyncratic, liquidity-driven move.

Technically, the stock remains in a corrective structure. It is trading below its 50-day simple moving average of about $4.36 and its 200-day average near $4.06, and Monday's high of $4.05 stalled almost exactly at that longer-term line. Support sits at the $3.67–$3.70 area; resistance is defined by the $4.05–$4.06 zone. The shares are down about 10% over the past month but still up roughly 40% year to date.

News Significance Score

The score runs from 0, meaning no meaningful news and a price move that is routine for the stock, to 100, meaning transformative news and an extreme, rare move. Oramed scores 19 out of 100.

The news component was very weak: no verified catalyst existed for Monday's session, and the most recent material event — a third-quarter report whose adjusted result was a loss — had already been published and digested. The price component was moderate: the 5.66% gain was about 2.95 times the stock's average absolute daily move of 1.92%, and a move of that size has occurred only three times in the last 60 sessions. Unusual, but not exceptional for a name that regularly swings several percent. Weak news and a moderately rare move combine into a low score.

What Comes Next for ORMP

The next scheduled catalyst is fourth-quarter and full-year 2026 results, expected in late March 2027. Until then, the stock's fair value will be driven by mark-to-market moves in its holdings, particularly Alpha Tau, whose clinical progress, regulatory submissions, and share price feed directly into Oramed's reported earnings.

Investors will also watch capital-return decisions — the company has paid dividends and bought back stock in the past — the trajectory of Lifeward, and any new portfolio allocations. The main risks are structural: no operating revenue means profit is hostage to non-cash revaluations, a single holding dominates net asset value, and thin liquidity can amplify moves in either direction. With no analyst coverage and modest institutional ownership, price discovery is likely to stay volatile.

Trending AI Robots

Tickeron operates hundreds of AI trading bots that cover thousands of tickers, but only the strongest performers under current market conditions make it into the curated Trending AI Robots section. The bots differ widely by strategy, timeframe, performance metrics, and the symbols they trade, so the list changes as market conditions shift. Reviewing the current leaders can help traders see which approaches are working right now and how they might complement their own research.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: ORMP

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


ORMP's Indicator enters downward trend

The Aroon Indicator for ORMP entered a downward trend on November 16, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 184 similar instances where the Aroon Indicator formed such a pattern. In 151 of the 184 cases the stock moved lower. This puts the odds of a downward move at 82%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ORMP as a result. In 72 of 90 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 80%.

The Moving Average Convergence Divergence Histogram (MACD) for ORMP turned negative on November 13, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 52 similar instances when the indicator turned negative. In 42 of the 52 cases the stock turned lower in the days that followed. This puts the odds of success at 81%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ORMP declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where ORMP's RSI Indicator exited the oversold zone, 25 of 29 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 86%.

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 48 of 62 cases where ORMP's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 77%.

ORMP may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron SMR rating for this company is 15 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is 59 (best 1 - 100 worst), indicating steady price growth. ORMP’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 67 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.506) is normal, around the industry mean (3.586). P/E Ratio (0.910) is within average values for comparable stocks, (-1.188). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.259) settles around the average of (130.981) among similar stocks. P/S Ratio (90.909) is also within normal values, averaging (440.869).

The Tickeron PE Growth Rating for this company is 94 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ORMP’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.23B. The market cap for tickers in the group ranges from 58 to 138.67B. VRTX holds the highest valuation in this group at 138.67B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -10%. For the same Industry, the average monthly price growth was -8%, and the average quarterly price growth was -22%. PEPG experienced the highest price growth at 75%, while ALGS experienced the biggest fall at -58%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was -24%. For the same stocks of the Industry, the average monthly volume growth was 6% and the average quarterly volume growth was -35%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 43
Price Growth Rating: 65
SMR Rating: 93
Profit Risk Rating: 93
Seasonality Score: -3 (-100 ... +100)
Trend Prediction Engine 4
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a company which engages in pharmaceutical preparations

Industry Biotechnology

Industry
Pharmaceuticals Other
Address
1185 Avenue of the Americas
Phone
+1 844 967-2633
Employees
13
Web
https://www.oramed.com
Interact to see
Advertisement
NVIDIA shares declined roughly 26% over the 30 days ending mid-November, falling from a close near $221 to $162.85. The drop left the stock about 30% below its October 6 record intraday high of $243.37 and at a 52-week low.
Micron shares fell -6.28% to $729.40 from Friday's $778.31 close, gapping lower in premarket trading and holding those losses into Monday's regular session. The decline was sector-driven, not company-specific: memory peers SanDisk, SK hynix and Western Digital slid in tandem as last week's Nvidia CEO departure revived doubts over AI data-center spending, financing and memory demand durability.
SKHY fell -6.87% to $122.74 by 10:04 a.m. ET, down $9.05 from Friday's close of $131.79, extending a premarket decline into the regular session. The drop was driven by a sector-wide AI chip selloff ahead of Nvidia's quarterly results on Tuesday, where CEO Jensen Huang's resignation has raised doubts about the durability of data-center spending that underpins high-bandwidth memory demand.
Dell Technologies (DELL) fell roughly 23.7% over the last 30 days, sliding from a closing price of $451.71 on October 16, 2026, to $344.53 on November 13, 2026. The decline accelerated after the U.S. midterm elections, when investor concerns about potential AI and data-center regulation triggered a sharp sell-off across AI hardware names.
ACHR fell -7.44% in Monday's regular session, sliding from Friday's $4.03 close to $3.73 shortly after 10 a.m. ET — a third consecutive daily decline that pushed shares back toward their November 5 low. No verified news or fundamental catalyst found for today's leg lower; the selling extends the de-rating that followed Q3 results — revenue of just $5.1 million, a net loss widening 111% to $274.6 million, and price-target cuts from Cantor Fitzgerald, Needham and Canaccord.